Mangalam Drugs And Organics Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mangalam Drugs and Organics has filed its audited standalone and consolidated results for Q4 and FY25, with a clean (unmodified) audit opinion from V.S. Somani & Co. Total income from operations declined about 14% YoY to Rs 31,823 lakhs (FY24: Rs 36,859 lakhs), but the company reported a sharp turnaround in profitability — standalone net profit swung from a loss of Rs 905 lakhs in FY24 to a profit of Rs 692 lakhs in FY25 (consolidated: Rs 672 lakhs vs loss of Rs 907 lakhs). EPS recovered to Rs 4.37 from a negative Rs 5.72 a year ago. Operating profit before other income jumped to Rs 1,942 lakhs (FY24: Rs 276 lakhs), with operating margin expanding meaningfully on lower raw material and stock-in-trade costs. The board also appointed a secretarial auditor for the upcoming financial year, and the previously announced merger scheme with Mangalam Laboratories and Shri JB Pharma remains pending NCLT approval.
The earnings show a clear recovery story — falling revenue but sharply improving margins and a return to profit, which should be viewed positively by shareholders. However, the Q4 standalone net profit of just Rs 15 lakhs (vs Rs 355 lakhs a year ago) signals softer momentum at year-end, and the pending merger with NCLT is an overhang to watch.